On 18.07. I bought shares in CapsoVision at USD 4.76 $CV in my portfolio.
The reason: the company is working on approval of its colon capsule - a product with great market potential in the field of capsule endoscopy. In the IPO prospectus and in analysts' comments, the colon market was described as having greater market potential than the current small intestine segment.
I have calculated three scenarios (example with 1000 shares):
🔹 Conservative (~6 USD): approx. 6,000 USD (+1.2k profit)
🔹 Moderate (~13.5 USD): Approx. 13,500 USD (+8.7k profit)
🔹 Aggressive (~30 USD): Approx. 30,000 USD (+25.2k profit)
Of course, this is not a guarantee, but a look at opportunities that could arise if CapsoVision makes the breakthrough.
👉 It will be particularly exciting to see how quickly the technology is accepted in practice and whether the colon capsule really changes the market.
What do you think? Gamechanger in MedTech or too much risk?
#aktien
#medtech
#wachstumsaktien
#capsovision
#investieren
#longterm
#chancen
#gesundheit
#getquin
#innovation
#börse
#dax
#nyse
#nasdaq
#invest
#medical
#medizin
#tenbagger
#aktie
